245 related articles for article (PubMed ID: 25058391)
1. Screening of ROS1 rearrangements in lung adenocarcinoma by immunohistochemistry and comparison with ALK rearrangements.
Cha YJ; Lee JS; Kim HR; Lim SM; Cho BC; Lee CY; Shim HS
PLoS One; 2014; 9(7):e103333. PubMed ID: 25058391
[TBL] [Abstract][Full Text] [Related]
2. Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK 'borderline'-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies.
Ilie MI; Bence C; Hofman V; Long-Mira E; Butori C; Bouhlel L; Lalvée S; Mouroux J; Poudenx M; Otto J; Marquette CH; Hofman P
Ann Oncol; 2015 Jan; 26(1):238-244. PubMed ID: 25344360
[TBL] [Abstract][Full Text] [Related]
3. ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas.
Sholl LM; Sun H; Butaney M; Zhang C; Lee C; Jänne PA; Rodig SJ
Am J Surg Pathol; 2013 Sep; 37(9):1441-9. PubMed ID: 23887156
[TBL] [Abstract][Full Text] [Related]
4. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
Mescam-Mancini L; Lantuéjoul S; Moro-Sibilot D; Rouquette I; Souquet PJ; Audigier-Valette C; Sabourin JC; Decroisette C; Sakhri L; Brambilla E; McLeer-Florin A
Lung Cancer; 2014 Feb; 83(2):168-73. PubMed ID: 24380695
[TBL] [Abstract][Full Text] [Related]
5. ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non-small cell lung cancer patients.
Bozzetti C; Nizzoli R; Tiseo M; Squadrilli A; Lagrasta C; Buti S; Gasparro D; Zanoni D; Majori M; De Filippo M; Mazzoni F; Maddau C; Naldi N; Sammarelli G; Frati C; Pinto C; Ardizzoni A
Diagn Cytopathol; 2015 Nov; 43(11):941-6. PubMed ID: 26152804
[TBL] [Abstract][Full Text] [Related]
6. ALK+ lung adenocarcinoma in never smokers and long-term ex-smokers: prevalence and detection by immunohistochemistry and fluorescence in situ hybridization.
Williams AS; Greer W; Bethune D; Craddock KJ; Flowerdew G; Xu Z
Virchows Arch; 2016 Nov; 469(5):533-540. PubMed ID: 27562706
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of a Dual ALK/ROS1 Fluorescent In Situ Hybridization Test in Non-Small-cell Lung Cancer.
Ginestet F; Lambros L; Le Flahec G; Marcorelles P; Uguen A
Clin Lung Cancer; 2018 Sep; 19(5):e647-e653. PubMed ID: 29801706
[TBL] [Abstract][Full Text] [Related]
8. ROS1 rearrangements define a unique molecular class of lung cancers.
Bergethon K; Shaw AT; Ou SH; Katayama R; Lovly CM; McDonald NT; Massion PP; Siwak-Tapp C; Gonzalez A; Fang R; Mark EJ; Batten JM; Chen H; Wilner KD; Kwak EL; Clark JW; Carbone DP; Ji H; Engelman JA; Mino-Kenudson M; Pao W; Iafrate AJ
J Clin Oncol; 2012 Mar; 30(8):863-70. PubMed ID: 22215748
[TBL] [Abstract][Full Text] [Related]
9. Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target.
Selinger CI; Li BT; Pavlakis N; Links M; Gill AJ; Lee A; Clarke S; Tran TN; Lum T; Yip PY; Horvath L; Yu B; Kohonen-Corish MR; O'Toole SA; Cooper WA
Histopathology; 2017 Feb; 70(3):402-411. PubMed ID: 27599111
[TBL] [Abstract][Full Text] [Related]
10. FISH patterns of ROS1, MET, and ALK with a correlation of ALK immunohistochemistry in lung cancer: a case for introducing ALK immunohistochemistry 'Equivocal' interpretation category in the Ventana anti-ALK (D5F3) CDx assay - A tertiary cancer center experience.
Singh A; Kumar R; Shetty O; Desai S; Rane S
Indian J Cancer; 2022; 59(1):18-25. PubMed ID: 33402590
[TBL] [Abstract][Full Text] [Related]
11. Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples.
Zito Marino F; Rossi G; Cozzolino I; Montella M; Micheli M; Bogina G; Munari E; Brunelli M; Franco R
J Clin Pathol; 2020 Feb; 73(2):96-101. PubMed ID: 31562206
[TBL] [Abstract][Full Text] [Related]
12. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.
Kim HR; Lim SM; Kim HJ; Hwang SK; Park JK; Shin E; Bae MK; Ou SH; Wang J; Jewell SS; Kang DR; Soo RA; Haack H; Kim JH; Shim HS; Cho BC
Ann Oncol; 2013 Sep; 24(9):2364-70. PubMed ID: 23788756
[TBL] [Abstract][Full Text] [Related]
13. Comparison of methods in the detection of ALK and ROS1 rearrangements in lung cancer.
Rogers TM; Russell PA; Wright G; Wainer Z; Pang JM; Henricksen LA; Singh S; Stanislaw S; Grille J; Roberts E; Solomon B; Fox SB
J Thorac Oncol; 2015 Apr; 10(4):611-8. PubMed ID: 25789833
[TBL] [Abstract][Full Text] [Related]
14. Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas.
Sholl LM; Weremowicz S; Gray SW; Wong KK; Chirieac LR; Lindeman NI; Hornick JL
J Thorac Oncol; 2013 Mar; 8(3):322-8. PubMed ID: 23407557
[TBL] [Abstract][Full Text] [Related]
15. Detection of ROS1 gene rearrangement in lung adenocarcinoma: comparison of IHC, FISH and real-time RT-PCR.
Shan L; Lian F; Guo L; Qiu T; Ling Y; Ying J; Lin D
PLoS One; 2015; 10(3):e0120422. PubMed ID: 25742289
[TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics and outcomes of patients with primary lung adenocarcinoma harboring ALK rearrangements detected by FISH, IHC, and RT-PCR.
Wang J; Cai Y; Dong Y; Nong J; Zhou L; Liu G; Su D; Li X; Wu S; Chen X; Qin N; Zeng X; Zhang H; Zhang Z; Zhang S
PLoS One; 2014; 9(7):e101551. PubMed ID: 24992725
[TBL] [Abstract][Full Text] [Related]
17. Cytology specimens offer an effective alternative to formalin-fixed tissue as demonstrated by novel automated detection for ALK break-apart FISH testing and immunohistochemistry in lung adenocarcinoma.
Rosenblum F; Hutchinson LM; Garver J; Woda B; Cosar E; Kurian EM
Cancer Cytopathol; 2014 Nov; 122(11):810-21. PubMed ID: 25099128
[TBL] [Abstract][Full Text] [Related]
18. Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer.
Lim SM; Chang H; Cha YJ; Liang S; Tai YC; Li G; Pestova E; Policht F; Perez T; Soo RA; Park WY; Kim HR; Shim HS; Cho BC
Lung Cancer; 2017 Sep; 111():79-83. PubMed ID: 28838404
[TBL] [Abstract][Full Text] [Related]
19. Ligation-dependent RT-PCR: a new specific and low-cost technique to detect ALK, ROS, and RET rearrangements in lung adenocarcinoma.
Piton N; Ruminy P; Gravet C; Marchand V; Colasse É; Lamy A; Naoures Mear CL; Bibeau F; Marguet F; Guisier F; Salaün M; Thiberville L; Jardin F; Sabourin JC
Lab Invest; 2018 Mar; 98(3):371-379. PubMed ID: 29251734
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas.
Nozaki Y; Yamamoto H; Iwasaki T; Sato M; Jiromaru R; Hongo T; Yasumatsu R; Oda Y
Hum Pathol; 2020 Dec; 106():82-92. PubMed ID: 32980422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
